[go: up one dir, main page]

BR9509478A - Antagonistas da progesterona competitivos para o controle de fertilidade feminina orientada de acordo com a necessidade - Google Patents

Antagonistas da progesterona competitivos para o controle de fertilidade feminina orientada de acordo com a necessidade

Info

Publication number
BR9509478A
BR9509478A BR9509478A BR9509478A BR9509478A BR 9509478 A BR9509478 A BR 9509478A BR 9509478 A BR9509478 A BR 9509478A BR 9509478 A BR9509478 A BR 9509478A BR 9509478 A BR9509478 A BR 9509478A
Authority
BR
Brazil
Prior art keywords
need
progesterone antagonists
competitive progesterone
female fertility
fertility control
Prior art date
Application number
BR9509478A
Other languages
English (en)
Inventor
Krzysztof Chwalisz
Klaus Stoeckermann
Karin Schmidt-Gollwitzer
Walter Klemann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR9509478A publication Critical patent/BR9509478A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
BR9509478A 1994-10-24 1995-10-24 Antagonistas da progesterona competitivos para o controle de fertilidade feminina orientada de acordo com a necessidade BR9509478A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4438820 1994-10-24
PCT/EP1995/004191 WO1996012494A1 (de) 1994-10-24 1995-10-24 Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle

Publications (1)

Publication Number Publication Date
BR9509478A true BR9509478A (pt) 1997-09-30

Family

ID=6532105

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9509478A BR9509478A (pt) 1994-10-24 1995-10-24 Antagonistas da progesterona competitivos para o controle de fertilidade feminina orientada de acordo com a necessidade

Country Status (25)

Country Link
US (1) US6143754A (pt)
EP (1) EP0787002B1 (pt)
JP (1) JPH10507461A (pt)
KR (1) KR970706827A (pt)
CN (1) CN1211087C (pt)
AT (1) ATE347894T1 (pt)
AU (1) AU707235B2 (pt)
BG (1) BG62877B1 (pt)
BR (1) BR9509478A (pt)
CA (1) CA2203541A1 (pt)
CZ (1) CZ290690B6 (pt)
DE (1) DE59511071D1 (pt)
DK (1) DK0787002T3 (pt)
ES (1) ES2279515T3 (pt)
FI (1) FI971742A (pt)
HU (1) HU226566B1 (pt)
IL (1) IL115738A (pt)
NO (1) NO314437B1 (pt)
NZ (1) NZ295365A (pt)
PL (1) PL319869A1 (pt)
PT (1) PT787002E (pt)
RO (1) RO120606B1 (pt)
SK (1) SK283662B6 (pt)
WO (1) WO1996012494A1 (pt)
ZA (1) ZA959008B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745085A1 (de) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP1605924B1 (en) * 1999-08-31 2008-11-05 Bayer Schering Pharma Aktiengesellschaft Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
IL148415A0 (en) * 1999-08-31 2002-09-12 Jenapharm Gmbh Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
JP2011507853A (ja) * 2007-12-20 2011-03-10 テバ ウィメンズ ヘルス インコーポレイテッド 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ
ES2574999T3 (es) * 2009-04-14 2016-06-23 Laboratoire Hra-Pharma Método para la contracepción a demanda usando levonorgestrel o norgestrel
PL2419108T3 (pl) 2009-04-14 2017-08-31 Laboratoire Hra Pharma Sposób antykoncepcji na żądanie
MX2015016121A (es) 2013-05-23 2016-03-31 Bayer Pharma AG Composicion farmaceutica, su uso y regimen de administracion para contracepcion a demanda.
AU2015350241B2 (en) 2014-11-17 2021-05-20 Context Biopharma Inc. Onapristone extended-release compositions and methods
EP3353148A4 (en) 2015-09-25 2019-04-24 Context Biopharma Inc. PROCESS FOR THE PRODUCTION OF ONAPRISTONE INTERMEDIATE PRODUCTS
US10548905B2 (en) 2015-12-15 2020-02-04 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein

Also Published As

Publication number Publication date
EP0787002A1 (de) 1997-08-06
MX9703018A (es) 1997-10-31
ZA959008B (en) 1996-09-16
NO314437B1 (no) 2003-03-24
FI971742A0 (fi) 1997-04-23
PT787002E (pt) 2007-03-30
US6143754A (en) 2000-11-07
SK283662B6 (sk) 2003-11-04
CN1211087C (zh) 2005-07-20
CA2203541A1 (en) 1996-05-02
AU3869695A (en) 1996-05-15
NO971869L (no) 1997-04-23
DE59511071D1 (de) 2007-01-25
KR970706827A (ko) 1997-12-01
IL115738A0 (en) 1996-01-19
FI971742A (fi) 1997-04-23
JPH10507461A (ja) 1998-07-21
SK51897A3 (en) 1997-09-10
WO1996012494A1 (de) 1996-05-02
BG62877B1 (bg) 2000-10-31
BG101427A (en) 1997-11-28
CZ290690B6 (cs) 2002-09-11
HU226566B1 (en) 2009-04-28
AU707235B2 (en) 1999-07-08
NO971869D0 (no) 1997-04-23
HUT77518A (hu) 1998-05-28
PL319869A1 (en) 1997-09-01
ATE347894T1 (de) 2007-01-15
DK0787002T3 (da) 2007-04-10
RO120606B1 (ro) 2006-05-30
CZ118097A3 (en) 1997-07-16
NZ295365A (en) 1999-07-29
CN1161649A (zh) 1997-10-08
IL115738A (en) 2002-05-23
ES2279515T3 (es) 2007-08-16
EP0787002B1 (de) 2006-12-13

Similar Documents

Publication Publication Date Title
BR9509478A (pt) Antagonistas da progesterona competitivos para o controle de fertilidade feminina orientada de acordo com a necessidade
PT806952E (pt) Antagonistas da progesterona para a preparacao de medicamentos para o tratamento de hemorragias uterinas disfuncionais
DK0402950T3 (da) Behandling af postmenopausale ulemper
ATE217192T1 (de) Kombinationsprodukt zur kontrazeption enthaltend progesteronantagonisten und gestagenen
ES2085337T3 (es) Comprimidos farmaceuticos.
ES2172592T3 (es) Agente antagonista de progesterona y agente gestageno para el tratamiento de la endometriosis y del liomioma uterino.
PT871453E (pt) Preparacao farmaceutica combinada de contracepcao combinada
BR0008057A (pt) Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada
BR9814136A (pt) Conjunto contraceptivo, processos de fabricação do mesmo e de tratamento de sangramento, usos de anti-progestogênio, de progestogênio e de anti-progestogênio, e, de um composto.
RS50283B (sr) Mezoprogestini za lečenje i prevenciju benignih ginekoloških poremećaja
TR199901958T2 (xx) �nfertiliteye kar�� ve fertiliteyi art�rmak i�in bir ila�.
HUP9900313A1 (hu) Antiösztrogének alkalmazása hím nemzőképesség szabályozására
PT1150683E (pt) Utilizacao de dienogest em doses elevadas
ES334076A1 (es) Un procedimiento para la preparacion de una composicion terapeutica.
KR960705553A (ko) 원하지 않는 고통을 멈추기 위한 니트로글리세린의 투약 방법
Crist Post-coital estrogen
JPS54544A (en) Computer composite system
FR2776925B3 (fr) Utilisation de derives d'aminothiazole pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: O INTERESSADO DEVERA APRESENTAR A COMPLEMENTACAO DA RETRIBUICAO REFERENTE A MANIFESTACAO SOBRE PARECER TECNICO ( CODIGO 216 ), DO DESPACHO PUBLICADO NA RPI 1820 DE 22/11/2005.